# Fig. S1




**Supplementary Figure 1. mAb UW80.1 binds specifically to human pDCs.** Peripheral blood obtained from healthy donors was stained with anti-CD14-PE, anti-CD123-FITC, Fc block, and either anti-BDCA2-biotin or mIgG1-biotin isotype control, followed by streptavidin-PerCP. Histograms depict binding of UW80.1 (open) or mIgG1 isotype control (filled) to CD14+ monocytes and CD123+ pDCs gated as shown. Results are representative of 2 individual donors.

# Fig. S2


A.
1μg
OVA-isotype
OVA-BDCA2
+/- 50μg R848
OTII
transfer
iv
iv
Day -1
0
1
pDCs analysis
B.
OVA-isotype
OVA-BDCA2
0.415
0.424
+R848
0.289
0.294
PDCA1
SiglecH
C.
count
isotype Ab
OVA-isotype
OVA-BDCA2
isotype Ab
OVA-isotype + R848
OVA-BDCA2 + R848
BDCA2
SiglecH
PDCA1
MHCII
CD40
CD9
MFI (BDCA2)
MFI (SiglecH)
MFI (PDCA1)
MFI (MHCII)
MFI (CD40)
MFI (CD9)
ns
*
**
***
OVA-isotype
OVA-BDCA2
OVA-isotype + R848
OVA-BDCA2+ R848
CD80
CD86
CD69
PD-L1
CCR9
CD95/Fas
MFI (CD80)
MFI (CD86)
MFI (CD69)
MFI (PD-L1)
MFI (CCR9)
MFI (Fas)

**Supplementary Figure 2. Phenotype of pDCs after OVA-BDCA2 immunization.** Cohorts of B6.BDCA2 mice recipients of OT-II cells were injected i.v. with 1 μg OVA-isotype or OVA-BDCA2 with or without 50 μg R848 and sacrificed 24 hours following injection. Splenic pDC were analyzed for the expression of indicated surface markers by flow cytometry (*A).* Schematic for immunization and subsequent analysis. *B,* Flow plots show the frequency of pDCs of gated live $CD19^-$ cells. *C*. Histograms show levels of expression of indicated surface marker in OVA-isotype or OVA-BDCA2-injected mice without adjuvant (upper rows), or in the presence of R848 (lower rows). Scatter plot depicts the mean fluorescent intensity (MFI) for individual markers in different groups. Each dot represents an individual animal with the mean indicated for each group (horizontal bars) ± SEM. * $p<0.05$, ** $p<0.01$, *** $p<0.001$, as determined by one-way ANOVA with Tukey post-test. Results are representative of 2 individual experiments.